Welcome to our dedicated page for Solana news (Ticker: HSDT), a resource for investors and traders seeking the latest updates and insights on Solana stock.
Solana Company reports developments as a Nasdaq-listed company with a digital asset treasury dedicated to acquiring and holding Solana tokens (SOL) and a legacy neurotechnology medical-device business. News commonly covers SOL accumulation, staking rewards, NAV-per-share capital strategy, ATM and registered-direct equity financing, share repurchases, and financial results shaped by digital-asset fair value changes.
Company updates also describe institutional Solana infrastructure initiatives in Asia-Pacific, including validator and staking infrastructure, qualified-custody borrowing against natively staked SOL, and ecosystem partnerships with organizations such as Jito Foundation, Anchorage Digital, and Kamino.
Summary not available.
Helius Medical Technologies (NASDAQ: HSDT), a neurotech company specializing in therapeutic neuromodulation for balance and gait deficits, has announced its participation in the LD Micro Invitational XIII 2023. The event will take place at the Luxe Sunset Boulevard Hotel in California.
President and CEO Dane Andreeff, along with CFO Jeff Mathiesen, will represent Helius at the conference. Their presentation is scheduled for Wednesday, June 7, 2023, at 4:00 PM PT. Interested parties can access the webcast through the provided link.
Investors and attendees wishing to arrange one-on-one meetings with Helius management are encouraged to contact LD Micro directly. This event provides an opportunity for Helius to showcase its innovative approach to neuromodulation therapy and engage with potential investors.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Helius Medical Technologies (NASDAQ: HSDT) will showcase its Portable Neuromodulation Stimulator (PoNS) device at the American Academy of Neurology (AAN) Annual Meeting for the first time since its launch in the U.S. and Canada. The device is authorized for use in managing gait deficits caused by multiple sclerosis, stroke, and mild-to-moderate traumatic brain injury. Helius reports promising clinical data, including over 55% average improvement in gait assessments among various patient groups. A notable finding includes 100% of MS participants improving their gait scores post-treatment. The AAN conference, held April 22-27, 2023, in Boston, allows for direct engagement with the medical team. This expansion of indications signals growing confidence in PoNS's efficacy and therapeutic potential.
Helius Medical Technologies (Nasdaq:HSDT) declared a dividend of one one-thousandth of a share of Series B Preferred Stock for each outstanding share of Class A common stock held on April 3, 2023. This new class of stock will have voting rights on specific amendments related to reclassification of Class A common stock. Each share of Series B Preferred Stock represents 1,000,000 votes, but will not be entitled to vote on other matters. Uncertificated, shares not present at a stockholder meeting will be redeemed for $0.001. Further details will be filed in a Form 8-K with the SEC.
Helius Medical Technologies (Nasdaq:HSDT) has announced an exclusive distribution agreement with HealthTech Connex (HTC) for the Portable Neuromodulation Stimulator (PoNS) device in the Vancouver area. This agreement replaces a previous partnership, granting HTC exclusive rights for purchase, marketing, and distribution over an initial five-year term, potentially extendable to ten years. Helius aims to enhance its market presence and improve the lives of patients with gait and balance impairments. Both companies express excitement over this collaboration, pivoting PoNS as a key solution for neurorehabilitation.
Helius Medical Technologies (Nasdaq:HSDT) reported a 51% revenue increase in 2022, totaling $787,000. Q4 revenue rose 9% year-over-year to $282,000. The company launched the UpScript Telehealth site for the PoNS® Therapy and added three Centers of Excellence to enhance patient access. Operating expenses decreased to $2.8 million in Q4, leading to a reduced operating loss of $2.7 million. Cash balance stood at $14.5 million at year-end. Helius anticipates revenue growth in 2023, contingent on third-party reimbursement developments.